In conclusion, this study identified ATP13A3 as a critical regulator of basal and DFMO‐induced polyamine uptake in MYCN‐amplified and non‐MYCN‐amplified neuroblastoma cells, which is targetable by the polyamine transport inhibitor AMXT 1501, and thereby highlights ATP13A3 as a novel therapeutic target for neuroblastoma (Fig. 10). The gene discussed is MYCN; the disease is neuroblastoma.